Mascarenhas L, Lyden ER, Breitfeld PP, et al. - For patients with rhabdomyosarcoma (RMS) at first relapse, researchers assessed risk and response–based multi-agent therapy. They randomized 136 patients with RMS and measurable disease at first relapse with unfavorable-risk (UR) characteristics to a 6-week phase 2 window with 1 of 2 treatment schedules of irinotecan with vincristine (previously reported). When treated with this multi-agent treatment, patients with UR RMS at first recurrence or disease progression have a bad prognosis, whereas favorable risk patients have a greater opportunity of being cured with second-line therapy. There have been no unexpected toxicities.